( November 11, 2024, 2:11 PM EST) -- NEW YORK — Arguments made by plaintiffs in the acetaminophen autism spectrum disorder-attention deficit hyperactivity disorder (ASD-ADHD) multidistrict litigation appealing a decision to exclude their expert witnesses “would transform the trial court’s role” in determining admissibility under Federal Rule of Evidence 702, Johnson & Johnson Consumer Inc. (JJCI) and retailers of acetaminophen argue in a brief before the Second Circuit Court U.S. Court of Appeals....